Research work · 2015

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew Xiuxuan Zhu, Joon Oh Park, Baek‐Yeol Ryoo

The Lancet Oncology

Read free full text

DOI: 10.1016/s1470-2045(15)00050-9